Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór lite, który się rozprzestrzenił lub nie nadaje się do operacji (np. rak jajnika, płuca, piersi).
- •Wcześniejsze skuteczne leczenie przeciwnowotworowe.
- •Zmiany nowotworowe widoczne w badaniach obrazowych (dla większości nowotworów).
- •Dla określonych typów raka jajnika: potwierdzony histologicznie lub cytologicznie, wysokiego stopnia złośliwości, oporny na platynę, po wcześniejszym leczeniu bevacizumabem lub jego odpowiednikiem.
- •Dla pacjentek z rakiem jajnika z mutacją BRCA: po leczeniu inhibitorem PARP, jeśli odpowiedziały na chemioterapię opartą na platynie.
✗ Disqualifies
- •Nowotwory inne niż wymienione w kryteriach włączenia.
- •Brak postępu choroby po ostatnim leczeniu.
- •Nieotrzymanie wcześniejszego leczenia bevacizumabem (dla określonych typów raka jajnika).
- •Chęć zajścia w ciążę lub karmienie piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (66)
USOR HonorHealth
Phoenix, United States
USOR Arizona Oncology Associates
Tucson, United States
University of California Los Angeles Medical Center
Los Angeles, United States
University of California, San Diego; Moores Cancer Center
San Diego, United States
USOR Sansum Clinic
Santa Barbara, United States
Providence Medical Foundation
Santa Rosa, United States
USOR Florida Cancer Specialists South
Fort Myers, United States
USOR Florida Cancer Specialists North
St. Petersburg, United States
USOR Florida Cancer Specialists East
West Palm Beach, United States
Augusta University Georgia Cancer Center
Augusta, United States
University of Kansas Medical Center (KUMC)
Westwood, United States
USOR Maryland Oncology Hematology
Rockville, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Karmanos Cancer Institute
Detroit, United States
START Midwest
Grand Rapids, United States
USOR Minnesota Oncology Hematology
Maplewood, United States
MD Anderson Cancer Center at Cooper- Two Cooper Plaza
Camden, United States
Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute
Columbus, United States
University of Oklahoma - Health Sciences Center
Oklahoma City, United States
USOR Oncology Associates of Oregon, P.C.
Eugene, United States
Compass Oncology - Rose Quarter
Portland, United States
USOR Alliance Cancer Specialist
Doylestown, United States
Allegheny Health Network
Pittsburgh, United States
Women and Infants Hospital of Rhode Island
Providence, United States
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, United States
Tennessee Oncology
Nashville, United States
USOR Texas Oncology
Abilene, United States
Texas Oncology - Central / South Texas
Austin, United States
Mary Crowley Cancer Research
Dallas, United States
USOR Texas Oncology
Fort Worth, United States
Texas Oncology - Northeast TX
Tyler, United States
USOR Texas Oncology Gulf Coast
Woodland, United States
START Mountain Region
West Valley City, United States
USOR Virginia Cancer Specialists
Fairfax, United States
USOR Virginia Oncology Associates
Norfolk, United States
Swedish Cancer Institute
Seattle, United States
Cancer hospital, Chinese Academy of Medical Sciences
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
Hunan Cancer Hospital - Phase 1
Changsha, China
Hunan Cancer Hospital - Thoracic Medicine Dept II
Changsha, China
Jiangxi Maternal and Child Health Hospital
Nanchang, China
Jilin Cancer Hospital
Changchun, China
Obstetrics & Gynecology Hospital of Fudan University
Chengdu, China
Fudan University Shanghai Cancer Center - Gynecologic Oncology
Shanghai, China
Fudan University Shanghai Cancer Center- Phase 1
Shanghai, China
Shanghai East Hospital
Shanghai, China
Sichuan Cancer Hospital
Shanghai, China
Zhejiang Cancer Hospital
Hangzhou, China
Fujian Cancer Hospital
Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangdong, China
Second Affiliated Hospital of Zhengzhou University
Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hubei, China
Second Hospital of Shanxi Medical University
Shanxi, China
Shanxi Cancer Hospital
Shanxi, China
Liaoning Cancer Hospital & Institute
Shengyang, China
Tianjin Cancer Hospital
Tianjin, China
Fukushima Medical University Hospital
Fukushima, Japan
Gunma Prefectural Cancer Center
Ōta, Japan
Sapporo Medical University Hospital
Sapporo, Japan
Hyogo Cancer Center
Akashi, Japan
Saitama Medical University-International Medical Center
Hidaka, Japan
Shizuoka Cancer Center
Nagaizumi-chō, Japan
Cancer Institute Hospital of JFCR
Koto, Japan
Keio University Hospital
Shinjuku-ku, Japan
Yamagata University Hospital
Yamagata, Japan
Trial contact
Genmab Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.